You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDabigatran etexilate
Accession NumberDB06695
TypeSmall Molecule
GroupsApproved
DescriptionDabigatran etexilate is an oral prodrug that is metabolized by a serum esterase to dabigatran. It is a synthetic, competitive and reversible direct thrombin inhibitor. Inhibition of thrombin disrupts the coagulation cascade and inhibits the formation of clots. Dabigatran etexilate may be used to decrease the risk of venous thromboembolic events in patients who have undergone total hip or knee replacement surgery, or to prevent stroke and systemic embolism in patients with atrial fibrillation, in whom anticoagulation therapy is indicated. In contrast to warfarin, because its anticoagulant effects are predictable, lab monitoring is not necessary. FDA approved on October 19, 2010.
Structure
Thumb
Synonyms
Dabigatran
Ethyl 3-[[[4-[[[(hexyloxyl)carbonyl]amino]iminomethyl]phenyl]amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl](pyridin-2-yl)amino] propanoate
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
PradaxaCapsule, hard75 mgOral useBoehringer Ingelheim International Gmb H2008-03-18Not applicableEu
PradaxaCapsule, hard150 mgOral useBoehringer Ingelheim International Gmb H2008-03-18Not applicableEu
Pradaxacapsule110 mg/1oralBoehringer Ingelheim Pharmaceuticals Inc.2015-11-23Not applicableUs
PradaxaCapsule, hard150 mgOral useBoehringer Ingelheim International Gmb H2008-03-18Not applicableEu
PradaxaCapsule, hard110 mgOral useBoehringer Ingelheim International Gmb H2008-03-18Not applicableEu
Pradaxacapsule75 mgoralBoehringer Ingelheim (Canada) Ltd Ltee2008-07-03Not applicableCanada
PradaxaCapsule, hard150 mgOral useBoehringer Ingelheim International Gmb H2008-03-18Not applicableEu
PradaxaCapsule, hard75 mgOral useBoehringer Ingelheim International Gmb H2008-03-18Not applicableEu
PradaxaCapsule, hard75 mgOral useBoehringer Ingelheim International Gmb H2008-03-18Not applicableEu
Pradaxacapsule150 mg/1oralBoehringer Ingelheim Pharmaceuticals Inc.2010-10-26Not applicableUs
PradaxaCapsule, hard150 mgOral useBoehringer Ingelheim International Gmb H2008-03-18Not applicableEu
PradaxaCapsule, hard110 mgOral useBoehringer Ingelheim International Gmb H2008-03-18Not applicableEu
Pradaxacapsule110 mgoralBoehringer Ingelheim (Canada) Ltd Ltee2008-07-03Not applicableCanada
PradaxaCapsule, hard110 mgOral useBoehringer Ingelheim International Gmb H2008-03-18Not applicableEu
PradaxaCapsule, hard110 mgOral useBoehringer Ingelheim International Gmb H2008-03-18Not applicableEu
PradaxaCapsule, hard75 mgOral useBoehringer Ingelheim International Gmb H2008-03-18Not applicableEu
Pradaxacapsule75 mg/1oralBoehringer Ingelheim Pharmaceuticals Inc.2011-08-08Not applicableUs
PradaxaCapsule, hard150 mgOral useBoehringer Ingelheim International Gmb H2008-03-18Not applicableEu
PradaxaCapsule, hard110 mgOral useBoehringer Ingelheim International Gmb H2008-03-18Not applicableEu
Pradaxacapsule150 mgoralBoehringer Ingelheim (Canada) Ltd Ltee2010-11-03Not applicableCanada
PradaxaCapsule, hard110 mgOral useBoehringer Ingelheim International Gmb H2008-03-18Not applicableEu
PradaxaCapsule, hard75 mgOral useBoehringer Ingelheim International Gmb H2008-03-18Not applicableEu
PradaxaCapsule, hard150 mgOral useBoehringer Ingelheim International Gmb H2008-03-18Not applicableEu
Pradaxacapsule150 mg/1oralRebel Distributors Corp2010-10-26Not applicableUs
PradaxaCapsule, hard150 mgOral useBoehringer Ingelheim International Gmb H2008-03-18Not applicableEu
PradaxaCapsule, hard110 mgOral useBoehringer Ingelheim International Gmb H2008-03-18Not applicableEu
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
PradaxBoehringer Ingelheim
RendixNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Dabigatran etexilate mesilate
Thumb
  • InChI Key: XETBXHPXHHOLOE-UHFFFAOYSA-N
  • Monoisotopic Mass: 723.305032141
  • Average Mass: 723.839
DBSALT000035
Categories
UNII2E18WX195X
CAS number211915-06-9
WeightAverage: 627.7332
Monoisotopic: 627.316917457
Chemical FormulaC34H41N7O5
InChI KeyInChIKey=KSGXQBZTULBEEQ-UHFFFAOYSA-N
InChI
InChI=1S/C34H41N7O5/c1-4-6-7-10-21-46-34(44)39-32(35)24-12-15-26(16-13-24)37-23-30-38-27-22-25(14-17-28(27)40(30)3)33(43)41(20-18-31(42)45-5-2)29-11-8-9-19-36-29/h8-9,11-17,19,22,37H,4-7,10,18,20-21,23H2,1-3H3,(H2,35,39,44)
IUPAC Name
ethyl 3-(1-{2-[({4-[amino({[(hexyloxy)carbonyl]imino})methyl]phenyl}amino)methyl]-1-methyl-1H-1,3-benzodiazol-5-yl}-N-(pyridin-2-yl)formamido)propanoate
SMILES
CCCCCCOC(=O)N=C(N)C1=CC=C(NCC2=NC3=C(C=CC(=C3)C(=O)N(CCC(=O)OCC)C3=CC=CC=N3)N2C)C=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzimidazoles. These are organic compounds containing a benzene ring fused to an imidazole ring (five member ring containing a nitrogen atom, 4 carbon atoms, and two double bonds).
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzimidazoles
Sub ClassNot Available
Direct ParentBenzimidazoles
Alternative Parents
Substituents
  • Benzimidazole
  • Benzamide
  • Phenylalkylamine
  • Substituted aniline
  • Benzoyl
  • Aralkylamine
  • Secondary aliphatic/aromatic amine
  • Aniline
  • Aminopyridine
  • Imidolactam
  • Benzenoid
  • Pyridine
  • N-substituted imidazole
  • Dicarboxylic acid or derivatives
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Imidazole
  • Azole
  • Tertiary amine
  • Carboxylic acid ester
  • Carboxamide group
  • Azacycle
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Carboximidamide
  • Secondary amine
  • Carboxylic acid derivative
  • Carboxylic acid amidine
  • Amidine
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationDabigatran is indicated for the prevention of venous thromboembolic events in patients who have undergone elective hip or knee replacement surgery (based on RE-NOVATE, RE-MODEL, and RE-MOBILIZE trials). In 2010, it was approved in the US and Canada for prevention of stroke and systemic embolism in patients with atrial fibrillation (approval based on the RE-LY trial). Contraindications: severe renal impairment (CrCL < 30 ml/min); haemorrhagic manifestations, bleeding diathesis or spontaneous or pharmacologic impairment of haemostasis; lesions at risk of clinically significant bleeding (e.g. extensive cerebral infarction (haemorrhagic or ischemic) in the last 6 months, active peptic ulcer disease); concomitant treatment with P-glycoprotein inhibitors (e.g. oral ketoconazole, verapamil); and those with known hypersensitivity to dabigatran, dabigatran etexilate or any ingredient used in the formulation or component of the container. As of December 2012, dabigatran is contraindicated in patients with mechanical prosthetic heart valves.
PharmacodynamicsDabigatran directly inhibits thrombin in a concentration-dependent, reversible, specific, and competitive manner which results in a prolongation of aPTT (partial thromboplastin time), ECT (Ecarin clotting time), and TT (thrombin time). It may increase INR but this laboratory parameter is relatively insensitive to the activity of dabigatran.
Mechanism of actionDabigatran etexilate is an inactive pro-drug that is converted to dabigatran, the active form, by esterase-catalyzed hydrolysis in the plasma and liver. Dabigatran, the main active principle in plasma, is a rapid-acting competitive and reversible direct inhibitor of thrombin. Thrombin, a serine protease, is responsible for the conversion of fibrinogen to fibrin in the coagulation cascade. Inhibition of thrombin consequently prevents thrombus development. Dabigatran inhibits free thrombin, fibrin-bound thrombin and thrombin-induced platelet aggregation.
Related Articles
AbsorptionPeak plasma concentrations were achieved in 6 hours in post surgical patients. In healthy patients, maximum concentrations were achieved in 0.5 to 2 hours. The absolute bioavailability of dabigatran in the body after administration of dabigatran etexilate was 6.5%. Food does not affect the bioavailability of dabigatran etexilate, but it delays the time to peak plasma concentrations by 2 hours. Oral bioavailability may increase by up to 75% when pellets are taken out of the hydroxypropylmethylcellulose (HPMC) capsule. Therefore, capsules should not be opened and pellets taken alone. Furthermore, although absorption of dabigatran etexilate is independent of gastrointestinal acidity, coadministration of pantoprazole (proton pump inhibitor) may reduce the bioavailability of dabigatran. Despite this finding, dose adjustment is not required.
Volume of distribution

Moderate tissue distribution with a Vd of 60-70L.
Accumulation factor, twice daily dosing = 2

Protein bindingRelatively low binding (34-35%) to plasma proteins.
Metabolism

CYP450 enzymes are not involved in the metabolism of dabigatran thus is not expected to interact with drugs metabolized by CYP isoenzymes. Dabigatran is typically metabolised by esterases and microsomal carboxylesterases. Pharmacologically active acylglucoronides are formed via conjugation. Four positional isomers, 1-O, 2-O, 3-O, and 4-O, acylglucuronides exist, each accounting for less than 10% of total plasma dabagatran.

Route of eliminationMainly excreted in urine (85%). Fecal excretion accounts for 6% of the orally administered dose. Dabigatran is primarily eliminated unchanged via the kidneys at a rate of 100 ml/min corresponding to the glomerular filtration rate.
Half life12-14 hours in healthy volunteers. 14-17 hours in patients treated for prevention of venous thromboembolism following hip- or knee-replacement surgery.
ClearanceNot Available
ToxicityThe most common adverse reactions include dyspepsia or gastritis-like symptoms. The approximate lethal dose (LD50) in rats and mice was observed at single oral doses of > 2000 mg/kg. Oral doses of 600 mg/kg did not induce any toxicologically meaningful changes in dogs and Rhesus monkeys. Dabigatran was well-tolerated in rats and Rhesus monkeys during repeat-dose toxicity studies. No evidence of mutagenic potential.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.942
Blood Brain Barrier+0.8673
Caco-2 permeable-0.7014
P-glycoprotein substrateSubstrate0.7412
P-glycoprotein inhibitor IInhibitor0.7539
P-glycoprotein inhibitor IIInhibitor0.8443
Renal organic cation transporterNon-inhibitor0.701
CYP450 2C9 substrateNon-substrate0.858
CYP450 2D6 substrateNon-substrate0.837
CYP450 3A4 substrateSubstrate0.6154
CYP450 1A2 substrateNon-inhibitor0.6906
CYP450 2C9 inhibitorNon-inhibitor0.5102
CYP450 2D6 inhibitorNon-inhibitor0.8417
CYP450 2C19 inhibitorInhibitor0.5157
CYP450 3A4 inhibitorInhibitor0.781
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5789
Ames testNon AMES toxic0.6292
CarcinogenicityNon-carcinogens0.8065
BiodegradationNot ready biodegradable0.9931
Rat acute toxicity2.7093 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9047
hERG inhibition (predictor II)Inhibitor0.6181
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Capsuleoral110 mg/1
Capsuleoral110 mg
Capsuleoral150 mg
Capsuleoral150 mg/1
Capsuleoral75 mg
Capsuleoral75 mg/1
Capsule, hardOral use110 mg
Capsule, hardOral use150 mg
Capsule, hardOral use75 mg
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6087380 No1998-02-182018-02-18Us
US7866474 No2007-08-312027-08-31Us
US7932273 No2005-09-072025-09-07Us
US9034822 No2011-01-202031-01-20Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point180 +/- 3 (DSC: 10 K min^-1 heating rate)Not Available
water solubility1.8mg/ml, partly soluble MSDS
logP3.8Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00466 mg/mLALOGPS
logP5.17ALOGPS
logP4.59ChemAxon
logS-5.1ALOGPS
pKa (Strongest Acidic)17.89ChemAxon
pKa (Strongest Basic)3.87ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area154.03 Å2ChemAxon
Rotatable Bond Count17ChemAxon
Refractivity176.43 m3·mol-1ChemAxon
Polarizability71.11 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Christian Filser, Wolfgang Dersch, Rainer Hamm, Arndt Hausherr, Gunter Koch, Ulrich Scholz, Georg Zerban, “METHOD FOR PRODUCING AN INTERMEDIATE PRODUCT OF DABIGATRAN ETEXILATE.” U.S. Patent US20110118471, issued May 19, 2011.

US20110118471
General References
  1. Bauer KA: New oral anticoagulants in development: potential for improved safety profiles. Rev Neurol Dis. 2010;7(1):1-8. [PubMed:20410856 ]
  2. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L: Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009 Sep 17;361(12):1139-51. doi: 10.1056/NEJMoa0905561. Epub 2009 Aug 30. [PubMed:19717844 ]
  3. Wolowacz SE, Roskell NS, Plumb JM, Caprini JA, Eriksson BI: Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis. Thromb Haemost. 2009 Jan;101(1):77-85. [PubMed:19132192 ]
  4. Ginsberg JS, Davidson BL, Comp PC, Francis CW, Friedman RJ, Huo MH, Lieberman JR, Muntz JE, Raskob GE, Clements ML, Hantel S, Schnee JM, Caprini JA: Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty. 2009 Jan;24(1):1-9. doi: 10.1016/j.arth.2008.01.132. Epub 2008 Apr 14. [PubMed:18534438 ]
  5. Eriksson BI, Dahl OE, Buller HR, Hettiarachchi R, Rosencher N, Bravo ML, Ahnfelt L, Piovella F, Stangier J, Kalebo P, Reilly P: A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost. 2005 Jan;3(1):103-11. [PubMed:15634273 ]
  6. Di Nisio M, Middeldorp S, Buller HR: Direct thrombin inhibitors. N Engl J Med. 2005 Sep 8;353(10):1028-40. [PubMed:16148288 ]
  7. Stangier J, Eriksson BI, Dahl OE, Ahnfelt L, Nehmiz G, Stahle H, Rathgen K, Svard R: Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol. 2005 May;45(5):555-63. [PubMed:15831779 ]
  8. Ezekowitz MD, Reilly PA, Nehmiz G, Simmers TA, Nagarakanti R, Parcham-Azad K, Pedersen KE, Lionetti DA, Stangier J, Wallentin L: Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol. 2007 Nov 1;100(9):1419-26. Epub 2007 Aug 17. [PubMed:17950801 ]
  9. Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Kalebo P, Christiansen AV, Hantel S, Hettiarachchi R, Schnee J, Buller HR: Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost. 2007 Nov;5(11):2178-85. [PubMed:17764540 ]
  10. Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Prins MH, Hettiarachchi R, Hantel S, Schnee J, Buller HR: Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet. 2007 Sep 15;370(9591):949-56. [PubMed:17869635 ]
  11. Scaglione F: New oral anticoagulants: comparative pharmacology with vitamin K antagonists. Clin Pharmacokinet. 2013 Feb;52(2):69-82. doi: 10.1007/s40262-012-0030-9. [PubMed:23292752 ]
External Links
ATC CodesB01AE07
AHFS Codes
  • 20:12.04.12
PDB EntriesNot Available
FDA labelDownload (431 KB)
MSDSDownload (99.2 KB)
Interactions
Drug Interactions
Drug
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with Dabigatran etexilate.
AbciximabDabigatran etexilate may increase the anticoagulant activities of Abciximab.
AceclofenacAceclofenac may increase the anticoagulant activities of Dabigatran etexilate.
AcenocoumarolDabigatran etexilate may increase the anticoagulant activities of Acenocoumarol.
AcetaminophenThe serum concentration of Dabigatran etexilate can be increased when it is combined with Acetaminophen.
Acetylsalicylic acidAcetylsalicylic acid may increase the anticoagulant activities of Dabigatran etexilate.
AdapaleneAdapalene may increase the anticoagulant activities of Dabigatran etexilate.
AfatinibThe serum concentration of Dabigatran etexilate can be increased when it is combined with Afatinib.
AlbendazoleThe serum concentration of Dabigatran etexilate can be increased when it is combined with Albendazole.
AldosteroneThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Aldosterone.
AlectinibThe serum concentration of Dabigatran etexilate can be increased when it is combined with Alectinib.
AlfentanilThe serum concentration of Dabigatran etexilate can be increased when it is combined with Alfentanil.
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Dabigatran etexilate.
AllylestrenolThe therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Allylestrenol.
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Dabigatran etexilate.
AlprostadilAlprostadil may increase the anticoagulant activities of Dabigatran etexilate.
AlteplaseAlteplase may increase the anticoagulant activities of Dabigatran etexilate.
AltrenogestThe therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Altrenogest.
Aluminum hydroxideThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Aluminum hydroxide.
Aluminum phosphateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Aluminum phosphate.
ALX-0081ALX-0081 may increase the anticoagulant activities of Dabigatran etexilate.
AmantadineThe serum concentration of Dabigatran etexilate can be increased when it is combined with Amantadine.
AmineptineThe serum concentration of Amineptine can be increased when it is combined with Dabigatran etexilate.
Aminohippuric acidThe serum concentration of Dabigatran etexilate can be increased when it is combined with Aminohippuric acid.
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Dabigatran etexilate.
Aminosalicylic AcidAminosalicylic Acid may increase the anticoagulant activities of Dabigatran etexilate.
AmiodaroneThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Amiodarone.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Dabigatran etexilate.
AmlodipineThe serum concentration of Dabigatran etexilate can be increased when it is combined with Amlodipine.
AmprenavirThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Amprenavir.
AmsacrineThe serum concentration of Dabigatran etexilate can be increased when it is combined with Amsacrine.
AnagrelideAnagrelide may increase the anticoagulant activities of Dabigatran etexilate.
AncrodDabigatran etexilate may increase the anticoagulant activities of Ancrod.
AnistreplaseAnistreplase may increase the anticoagulant activities of Dabigatran etexilate.
AntipyrineAntipyrine may increase the anticoagulant activities of Dabigatran etexilate.
Antithrombin III humanDabigatran etexilate may increase the anticoagulant activities of Antithrombin III human.
ApixabanApixaban may increase the anticoagulant activities of Dabigatran etexilate.
ApremilastApremilast may increase the anticoagulant activities of Dabigatran etexilate.
AprotininThe therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Aprotinin.
ArdeparinDabigatran etexilate may increase the anticoagulant activities of Ardeparin.
ArgatrobanDabigatran etexilate may increase the anticoagulant activities of Argatroban.
AstaxanthinAstaxanthin may increase the anticoagulant activities of Dabigatran etexilate.
AstemizoleThe serum concentration of Dabigatran etexilate can be increased when it is combined with Astemizole.
AtazanavirThe serum concentration of Dabigatran etexilate can be increased when it is combined with Atazanavir.
AtenololThe serum concentration of Dabigatran etexilate can be increased when it is combined with Atenolol.
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Dabigatran etexilate.
AtorvastatinThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Atorvastatin.
AzapropazoneAzapropazone may increase the anticoagulant activities of Dabigatran etexilate.
AzelastineAzelastine may increase the anticoagulant activities of Dabigatran etexilate.
AzithromycinThe serum concentration of Dabigatran etexilate can be increased when it is combined with Azithromycin.
BalsalazideBalsalazide may increase the anticoagulant activities of Dabigatran etexilate.
BatroxobinBatroxobin may increase the anticoagulant activities of Dabigatran etexilate.
BazedoxifeneBazedoxifene may decrease the anticoagulant activities of Dabigatran etexilate.
BecaplerminDabigatran etexilate may increase the anticoagulant activities of Becaplermin.
BemiparinBemiparin may increase the anticoagulant activities of Dabigatran etexilate.
BenoxaprofenBenoxaprofen may increase the anticoagulant activities of Dabigatran etexilate.
BenzocaineThe serum concentration of Dabigatran etexilate can be increased when it is combined with Benzocaine.
BepridilThe serum concentration of Dabigatran etexilate can be increased when it is combined with Bepridil.
BeraprostBeraprost may increase the anticoagulant activities of Dabigatran etexilate.
BiperidenThe serum concentration of Dabigatran etexilate can be increased when it is combined with Biperiden.
Bismuth SubcitrateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Bismuth Subcitrate.
BivalirudinDabigatran etexilate may increase the anticoagulant activities of Bivalirudin.
BoceprevirThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Boceprevir.
BosutinibThe serum concentration of Dabigatran etexilate can be increased when it is combined with Bosutinib.
BromfenacBromfenac may increase the anticoagulant activities of Dabigatran etexilate.
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Dabigatran etexilate.
BuprenorphineThe serum concentration of Dabigatran etexilate can be increased when it is combined with Buprenorphine.
BuspironeThe serum concentration of Dabigatran etexilate can be increased when it is combined with Buspirone.
CabazitaxelThe serum concentration of Dabigatran etexilate can be increased when it is combined with Cabazitaxel.
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Dabigatran etexilate.
CaffeineThe serum concentration of Dabigatran etexilate can be increased when it is combined with Caffeine.
Calcium carbonateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Calcium carbonate.
CanagliflozinThe serum concentration of Dabigatran etexilate can be increased when it is combined with Canagliflozin.
CandesartanThe serum concentration of Dabigatran etexilate can be increased when it is combined with Candesartan.
CangrelorCangrelor may increase the anticoagulant activities of Dabigatran etexilate.
CaptoprilThe serum concentration of Dabigatran etexilate can be increased when it is combined with Captopril.
CarbamazepineThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Carbamazepine.
CarprofenCarprofen may increase the anticoagulant activities of Dabigatran etexilate.
CarvedilolThe serum concentration of Dabigatran etexilate can be increased when it is combined with Carvedilol.
CaspofunginThe serum concentration of Dabigatran etexilate can be increased when it is combined with Caspofungin.
CastanospermineCastanospermine may increase the anticoagulant activities of Dabigatran etexilate.
CelecoxibCelecoxib may increase the anticoagulant activities of Dabigatran etexilate.
CertoparinDabigatran etexilate may increase the anticoagulant activities of Certoparin.
ChloroquineChloroquine may increase the anticoagulant activities of Dabigatran etexilate.
ChlorotrianiseneChlorotrianisene may decrease the anticoagulant activities of Dabigatran etexilate.
ChlorpromazineThe serum concentration of Dabigatran etexilate can be increased when it is combined with Chlorpromazine.
ChlorpropamideThe serum concentration of Dabigatran etexilate can be increased when it is combined with Chlorpropamide.
ChlorprothixeneThe serum concentration of Dabigatran etexilate can be increased when it is combined with Chlorprothixene.
CholesterolThe serum concentration of Dabigatran etexilate can be increased when it is combined with Cholesterol.
Cholic AcidThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Cholic Acid.
CilazaprilThe serum concentration of Dabigatran etexilate can be increased when it is combined with Cilazapril.
CilostazolCilostazol may increase the anticoagulant activities of Dabigatran etexilate.
CimetidineThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Cimetidine.
CiprofloxacinThe serum concentration of Dabigatran etexilate can be increased when it is combined with Ciprofloxacin.
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Dabigatran etexilate.
CitalopramThe serum concentration of Dabigatran etexilate can be increased when it is combined with Citalopram.
Citric AcidDabigatran etexilate may increase the anticoagulant activities of Citric Acid.
ClarithromycinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Dabigatran etexilate.
ClarithromycinThe serum concentration of Dabigatran etexilate can be increased when it is combined with Clarithromycin.
ClofazimineThe serum concentration of Dabigatran etexilate can be increased when it is combined with Clofazimine.
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Dabigatran etexilate.
ClonixinClonixin may increase the anticoagulant activities of Dabigatran etexilate.
ClopidogrelClopidogrel may increase the anticoagulant activities of Dabigatran etexilate.
ClotrimazoleThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Clotrimazole.
CobicistatThe serum concentration of Dabigatran etexilate can be increased when it is combined with Cobicistat.
ColchicineThe serum concentration of Dabigatran etexilate can be increased when it is combined with Colchicine.
ColforsinThe serum concentration of Dabigatran etexilate can be increased when it is combined with Colforsin.
CollagenaseThe risk or severity of adverse effects can be increased when Dabigatran etexilate is combined with Collagenase.
Conjugated Equine EstrogensConjugated Equine Estrogens may decrease the anticoagulant activities of Dabigatran etexilate.
CrizotinibThe serum concentration of Dabigatran etexilate can be increased when it is combined with Crizotinib.
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be increased when it is combined with Dabigatran etexilate.
CyclophosphamideThe risk or severity of adverse effects can be increased when Dabigatran etexilate is combined with Cyclophosphamide.
CyclophosphamideThe serum concentration of Dabigatran etexilate can be increased when it is combined with Cyclophosphamide.
CyclosporineThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Cyclosporine.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Dabigatran etexilate.
D-LimoneneD-Limonene may increase the anticoagulant activities of Dabigatran etexilate.
DaclatasvirThe serum concentration of Dabigatran etexilate can be increased when it is combined with Daclatasvir.
DactinomycinThe serum concentration of Dabigatran etexilate can be increased when it is combined with Dactinomycin.
DalteparinDabigatran etexilate may increase the anticoagulant activities of Dalteparin.
DanaparoidDabigatran etexilate may increase the anticoagulant activities of Danaparoid.
DasatinibDasatinib may increase the anticoagulant activities of Dabigatran etexilate.
DaunorubicinThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Daunorubicin.
DeferasiroxThe risk or severity of adverse effects can be increased when Dabigatran etexilate is combined with Deferasirox.
DefibrotideDefibrotide may increase the anticoagulant activities of Dabigatran etexilate.
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Dabigatran etexilate.
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Dabigatran etexilate is combined with Deoxycholic Acid.
DesipramineThe serum concentration of Desipramine can be increased when it is combined with Dabigatran etexilate.
DesirudinDabigatran etexilate may increase the anticoagulant activities of Desirudin.
DesloratadineThe serum concentration of Dabigatran etexilate can be increased when it is combined with Desloratadine.
DesmoteplaseDesmoteplase may increase the anticoagulant activities of Dabigatran etexilate.
DesogestrelThe therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Desogestrel.
DexamethasoneThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Dexamethasone.
DextranDabigatran etexilate may increase the anticoagulant activities of Dextran.
Dextran 40Dabigatran etexilate may increase the anticoagulant activities of Dextran 40.
Dextran 70Dabigatran etexilate may increase the anticoagulant activities of Dextran 70.
Dextran 75Dabigatran etexilate may increase the anticoagulant activities of Dextran 75.
DextromethorphanThe serum concentration of Dabigatran etexilate can be increased when it is combined with Dextromethorphan.
DiclofenacDiclofenac may increase the anticoagulant activities of Dabigatran etexilate.
DicoumarolDabigatran etexilate may increase the anticoagulant activities of Dicoumarol.
DienestrolDienestrol may decrease the anticoagulant activities of Dabigatran etexilate.
DienogestThe therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Dienogest.
DiethylstilbestrolDiethylstilbestrol may decrease the anticoagulant activities of Dabigatran etexilate.
DiflunisalDiflunisal may increase the anticoagulant activities of Dabigatran etexilate.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Dabigatran etexilate.
DigoxinThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Digoxin.
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Dabigatran etexilate.
DiltiazemThe serum concentration of Dabigatran etexilate can be increased when it is combined with Diltiazem.
DipyridamoleDipyridamole may increase the anticoagulant activities of Dabigatran etexilate.
DitazoleDitazole may increase the anticoagulant activities of Dabigatran etexilate.
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Dabigatran etexilate.
DoxazosinThe serum concentration of Dabigatran etexilate can be increased when it is combined with Doxazosin.
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Dabigatran etexilate.
DoxorubicinThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Doxorubicin.
DronabinolThe serum concentration of Dabigatran etexilate can be increased when it is combined with Dronabinol.
DronedaroneThe serum concentration of Dabigatran etexilate can be increased when it is combined with Dronedarone.
DrospirenoneThe therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Drospirenone.
Drotrecogin alfaDrotrecogin alfa may increase the anticoagulant activities of Dabigatran etexilate.
DroxicamDroxicam may increase the anticoagulant activities of Dabigatran etexilate.
DydrogesteroneThe therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Dydrogesterone.
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Dabigatran etexilate.
Edetic AcidDabigatran etexilate may increase the anticoagulant activities of Edetic Acid.
EdoxabanDabigatran etexilate may increase the anticoagulant activities of Edoxaban.
ElbasvirThe serum concentration of Dabigatran etexilate can be increased when it is combined with Elbasvir.
EnalaprilThe serum concentration of Dabigatran etexilate can be increased when it is combined with Enalapril.
EnfuvirtideThe serum concentration of Enfuvirtide can be increased when it is combined with Dabigatran etexilate.
EnoxaparinDabigatran etexilate may increase the anticoagulant activities of Enoxaparin.
EnzalutamideThe serum concentration of Dabigatran etexilate can be increased when it is combined with Enzalutamide.
EpinastineEpinastine may increase the anticoagulant activities of Dabigatran etexilate.
EpirizoleEpirizole may increase the anticoagulant activities of Dabigatran etexilate.
EpoprostenolEpoprostenol may increase the anticoagulant activities of Dabigatran etexilate.
EpoprostenolThe risk or severity of adverse effects can be increased when Dabigatran etexilate is combined with Epoprostenol.
EptifibatideEptifibatide may increase the anticoagulant activities of Dabigatran etexilate.
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Dabigatran etexilate.
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Dabigatran etexilate.
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Dabigatran etexilate.
ErythromycinThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Erythromycin.
EsmirtazapineThe serum concentration of Esmirtazapine can be increased when it is combined with Dabigatran etexilate.
EsomeprazoleThe serum concentration of the active metabolites of Dabigatran etexilate can be reduced when Dabigatran etexilate is used in combination with Esomeprazole resulting in a loss in efficacy.
EstradiolEstradiol may decrease the anticoagulant activities of Dabigatran etexilate.
EstramustineThe serum concentration of Dabigatran etexilate can be increased when it is combined with Estramustine.
EstriolThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Estriol.
EstroneThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Estrone.
EtanerceptEtanercept may increase the anticoagulant activities of Dabigatran etexilate.
Ethinyl EstradiolEthinyl Estradiol may decrease the anticoagulant activities of Dabigatran etexilate.
Ethyl biscoumacetateDabigatran etexilate may increase the anticoagulant activities of Ethyl biscoumacetate.
EtodolacEtodolac may increase the anticoagulant activities of Dabigatran etexilate.
EtofenamateEtofenamate may increase the anticoagulant activities of Dabigatran etexilate.
EtonogestrelThe therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Etonogestrel.
EtoposideThe serum concentration of Dabigatran etexilate can be increased when it is combined with Etoposide.
EtoricoxibEtoricoxib may increase the anticoagulant activities of Dabigatran etexilate.
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Dabigatran etexilate.
EtravirineThe serum concentration of Dabigatran etexilate can be increased when it is combined with Etravirine.
Evening primrose oilEvening primrose oil may increase the anticoagulant activities of Dabigatran etexilate.
exisulindexisulind may increase the anticoagulant activities of Dabigatran etexilate.
FelodipineThe serum concentration of Dabigatran etexilate can be increased when it is combined with Felodipine.
FenbufenFenbufen may increase the anticoagulant activities of Dabigatran etexilate.
FenoprofenFenoprofen may increase the anticoagulant activities of Dabigatran etexilate.
FentanylThe serum concentration of Dabigatran etexilate can be increased when it is combined with Fentanyl.
FexofenadineThe serum concentration of Dabigatran etexilate can be increased when it is combined with Fexofenadine.
FibrinolysinFibrinolysin may increase the anticoagulant activities of Dabigatran etexilate.
FidaxomicinThe serum concentration of Dabigatran etexilate can be increased when it is combined with Fidaxomicin.
FloctafenineFloctafenine may increase the anticoagulant activities of Dabigatran etexilate.
FluconazoleThe serum concentration of Dabigatran etexilate can be increased when it is combined with Fluconazole.
FlunixinFlunixin may increase the anticoagulant activities of Dabigatran etexilate.
FluoxetineThe serum concentration of Dabigatran etexilate can be increased when it is combined with Fluoxetine.
FlupentixolThe serum concentration of Dabigatran etexilate can be increased when it is combined with Flupentixol.
FluphenazineThe serum concentration of Dabigatran etexilate can be increased when it is combined with Fluphenazine.
FlurazepamThe serum concentration of Dabigatran etexilate can be increased when it is combined with Flurazepam.
FlurbiprofenFlurbiprofen may increase the anticoagulant activities of Dabigatran etexilate.
FluvoxamineThe serum concentration of Dabigatran etexilate can be increased when it is combined with Fluvoxamine.
Fondaparinux sodiumDabigatran etexilate may increase the anticoagulant activities of Fondaparinux sodium.
GarlicThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Garlic.
GefitinibThe serum concentration of Dabigatran etexilate can be increased when it is combined with Gefitinib.
GenisteinThe serum concentration of Dabigatran etexilate can be increased when it is combined with Genistein.
GestodeneThe therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Gestodene.
GlyburideThe serum concentration of Dabigatran etexilate can be increased when it is combined with Glyburide.
GlycerolThe serum concentration of Dabigatran etexilate can be increased when it is combined with Glycerol.
Gramicidin DThe serum concentration of Dabigatran etexilate can be increased when it is combined with Gramicidin D.
GrepafloxacinThe serum concentration of Dabigatran etexilate can be increased when it is combined with Grepafloxacin.
HaloperidolThe serum concentration of Dabigatran etexilate can be increased when it is combined with Haloperidol.
HeminHemin may increase the anticoagulant activities of Dabigatran etexilate.
HeparinDabigatran etexilate may increase the anticoagulant activities of Heparin.
HexestrolHexestrol may decrease the anticoagulant activities of Dabigatran etexilate.
HirulogDabigatran etexilate may increase the anticoagulant activities of Hirulog.
HMPL-004HMPL-004 may increase the anticoagulant activities of Dabigatran etexilate.
HydrocortisoneThe serum concentration of Dabigatran etexilate can be increased when it is combined with Hydrocortisone.
Hydroxyprogesterone caproateThe therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Hydroxyprogesterone caproate.
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Dabigatran etexilate is combined with Ibritumomab tiuxetan.
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Dabigatran etexilate.
IbudilastIbudilast may increase the anticoagulant activities of Dabigatran etexilate.
IbuprofenIbuprofen may increase the anticoagulant activities of Dabigatran etexilate.
IbuproxamIbuproxam may increase the anticoagulant activities of Dabigatran etexilate.
IcatibantIcatibant may increase the anticoagulant activities of Dabigatran etexilate.
Icosapent ethylIcosapent ethyl may increase the anticoagulant activities of Dabigatran etexilate.
IdelalisibThe serum concentration of Dabigatran etexilate can be increased when it is combined with Idelalisib.
IfenprodilIfenprodil may increase the anticoagulant activities of Dabigatran etexilate.
IloprostIloprost may increase the anticoagulant activities of Dabigatran etexilate.
IloprostThe risk or severity of adverse effects can be increased when Dabigatran etexilate is combined with Iloprost.
ImatinibThe serum concentration of Dabigatran etexilate can be increased when it is combined with Imatinib.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Dabigatran etexilate.
IndinavirThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Indinavir.
IndomethacinIndomethacin may increase the anticoagulant activities of Dabigatran etexilate.
IndoprofenIndoprofen may increase the anticoagulant activities of Dabigatran etexilate.
IsavuconazoniumThe serum concentration of Dabigatran etexilate can be increased when it is combined with Isavuconazonium.
IsoxicamIsoxicam may increase the anticoagulant activities of Dabigatran etexilate.
ItraconazoleThe serum concentration of Dabigatran etexilate can be increased when it is combined with Itraconazole.
IvacaftorThe serum concentration of Dabigatran etexilate can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Dabigatran etexilate can be increased when it is combined with Ivermectin.
KebuzoneKebuzone may increase the anticoagulant activities of Dabigatran etexilate.
KetamineThe serum concentration of Dabigatran etexilate can be increased when it is combined with Ketamine.
KetoconazoleThe serum concentration of Dabigatran etexilate can be increased when it is combined with Ketoconazole.
KetoprofenKetoprofen may increase the anticoagulant activities of Dabigatran etexilate.
KetorolacKetorolac may increase the anticoagulant activities of Dabigatran etexilate.
LansoprazoleThe serum concentration of the active metabolites of Dabigatran etexilate can be reduced when Dabigatran etexilate is used in combination with Lansoprazole resulting in a loss in efficacy.
LapatinibThe serum concentration of Dabigatran etexilate can be increased when it is combined with Lapatinib.
LeflunomideLeflunomide may increase the anticoagulant activities of Dabigatran etexilate.
LepirudinDabigatran etexilate may increase the anticoagulant activities of Lepirudin.
LevofloxacinThe serum concentration of Dabigatran etexilate can be increased when it is combined with Levofloxacin.
LevonorgestrelThe therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Levonorgestrel.
LevothyroxineThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Levothyroxine.
LidocaineThe serum concentration of Dabigatran etexilate can be increased when it is combined with Lidocaine.
LimaprostThe risk or severity of adverse effects can be increased when Limaprost is combined with Dabigatran etexilate.
LiothyronineThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Liothyronine.
LiotrixThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Liotrix.
LisinoprilThe serum concentration of Dabigatran etexilate can be increased when it is combined with Lisinopril.
LomitapideThe serum concentration of Dabigatran etexilate can be increased when it is combined with Lomitapide.
LoperamideThe serum concentration of Dabigatran etexilate can be increased when it is combined with Loperamide.
LopinavirThe serum concentration of Dabigatran etexilate can be increased when it is combined with Lopinavir.
LoratadineThe serum concentration of Dabigatran etexilate can be increased when it is combined with Loratadine.
LornoxicamLornoxicam may increase the anticoagulant activities of Dabigatran etexilate.
LosartanThe serum concentration of Dabigatran etexilate can be increased when it is combined with Losartan.
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Dabigatran etexilate.
LoxoprofenLoxoprofen may increase the anticoagulant activities of Dabigatran etexilate.
LumacaftorThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Lumacaftor.
LumiracoxibLumiracoxib may increase the anticoagulant activities of Dabigatran etexilate.
MagaldrateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Magaldrate.
Magnesium carbonateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Magnesium carbonate.
Magnesium hydroxideThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Magnesium hydroxide.
Magnesium oxideThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Magnesium oxide.
Magnesium salicylateMagnesium salicylate may increase the anticoagulant activities of Dabigatran etexilate.
Magnesium TrisilicateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Magnesium Trisilicate.
MaprotilineThe serum concentration of Dabigatran etexilate can be increased when it is combined with Maprotiline.
MasoprocolMasoprocol may increase the anticoagulant activities of Dabigatran etexilate.
MebendazoleThe serum concentration of Dabigatran etexilate can be increased when it is combined with Mebendazole.
Meclofenamic acidMeclofenamic acid may increase the anticoagulant activities of Dabigatran etexilate.
MedrogestoneThe therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Medrogestone.
Medroxyprogesterone acetateThe therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Medroxyprogesterone acetate.
Mefenamic acidMefenamic acid may increase the anticoagulant activities of Dabigatran etexilate.
MefloquineThe serum concentration of Dabigatran etexilate can be increased when it is combined with Mefloquine.
Megestrol acetateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Megestrol acetate.
MeloxicamMeloxicam may increase the anticoagulant activities of Dabigatran etexilate.
MeprobamateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Meprobamate.
MesalazineMesalazine may increase the anticoagulant activities of Dabigatran etexilate.
MestranolMestranol may decrease the anticoagulant activities of Dabigatran etexilate.
MetamizoleMetamizole may increase the anticoagulant activities of Dabigatran etexilate.
MethadoneThe serum concentration of Dabigatran etexilate can be increased when it is combined with Methadone.
MetoprololThe serum concentration of Dabigatran etexilate can be increased when it is combined with Metoprolol.
MibefradilThe serum concentration of Dabigatran etexilate can be increased when it is combined with Mibefradil.
MiconazoleThe serum concentration of Dabigatran etexilate can be increased when it is combined with Miconazole.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Dabigatran etexilate.
MidazolamThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Midazolam.
MifepristoneThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Mifepristone.
MilrinoneMilrinone may increase the anticoagulant activities of Dabigatran etexilate.
MirtazapineThe serum concentration of Mirtazapine can be increased when it is combined with Dabigatran etexilate.
MitomycinThe serum concentration of Dabigatran etexilate can be increased when it is combined with Mitomycin.
MitoxantroneThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Mitoxantrone.
MorphineThe serum concentration of Dabigatran etexilate can be increased when it is combined with Morphine.
Mycophenolate mofetilMycophenolate mofetil may increase the anticoagulant activities of Dabigatran etexilate.
Mycophenolic acidMycophenolic acid may increase the anticoagulant activities of Dabigatran etexilate.
NabumetoneNabumetone may increase the anticoagulant activities of Dabigatran etexilate.
NadroparinDabigatran etexilate may increase the anticoagulant activities of Nadroparin.
NaftifineNaftifine may increase the anticoagulant activities of Dabigatran etexilate.
NaltrexoneThe serum concentration of Dabigatran etexilate can be increased when it is combined with Naltrexone.
NaproxenNaproxen may increase the anticoagulant activities of Dabigatran etexilate.
NaringeninThe serum concentration of Dabigatran etexilate can be increased when it is combined with Naringenin.
NCX 4016NCX 4016 may increase the anticoagulant activities of Dabigatran etexilate.
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with Dabigatran etexilate.
NefazodoneThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Nefazodone.
NelfinavirThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Nelfinavir.
NeostigmineThe serum concentration of Dabigatran etexilate can be increased when it is combined with Neostigmine.
NepafenacNepafenac may increase the anticoagulant activities of Dabigatran etexilate.
NicardipineThe serum concentration of Dabigatran etexilate can be increased when it is combined with Nicardipine.
NifedipineThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Nifedipine.
Niflumic AcidNiflumic Acid may increase the anticoagulant activities of Dabigatran etexilate.
NilotinibThe serum concentration of Dabigatran etexilate can be increased when it is combined with Nilotinib.
NimesulideNimesulide may increase the anticoagulant activities of Dabigatran etexilate.
NintedanibThe risk or severity of adverse effects can be increased when Dabigatran etexilate is combined with Nintedanib.
NisoldipineThe serum concentration of Dabigatran etexilate can be increased when it is combined with Nisoldipine.
NitrazepamThe serum concentration of Dabigatran etexilate can be increased when it is combined with Nitrazepam.
NitrendipineThe serum concentration of Dabigatran etexilate can be increased when it is combined with Nitrendipine.
NorethisteroneThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Norethisterone.
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Dabigatran etexilate.
ObinutuzumabThe risk or severity of adverse effects can be increased when Dabigatran etexilate is combined with Obinutuzumab.
OlopatadineOlopatadine may increase the anticoagulant activities of Dabigatran etexilate.
OlsalazineOlsalazine may increase the anticoagulant activities of Dabigatran etexilate.
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Dabigatran etexilate is combined with Omacetaxine mepesuccinate.
Omega-3 fatty acidsOmega-3 fatty acids may increase the anticoagulant activities of Dabigatran etexilate.
OmeprazoleThe serum concentration of the active metabolites of Dabigatran etexilate can be reduced when Dabigatran etexilate is used in combination with Omeprazole resulting in a loss in efficacy.
OrgoteinOrgotein may increase the anticoagulant activities of Dabigatran etexilate.
OtamixabanDabigatran etexilate may increase the anticoagulant activities of Otamixaban.
OxaprozinOxaprozin may increase the anticoagulant activities of Dabigatran etexilate.
OxyphenbutazoneOxyphenbutazone may increase the anticoagulant activities of Dabigatran etexilate.
P-NitrophenolThe serum concentration of Dabigatran etexilate can be increased when it is combined with P-Nitrophenol.
PaclitaxelThe serum concentration of Dabigatran etexilate can be increased when it is combined with Paclitaxel.
Palmitic AcidThe serum concentration of Dabigatran etexilate can be increased when it is combined with Palmitic Acid.
PantoprazoleThe serum concentration of the active metabolites of Dabigatran etexilate can be reduced when Dabigatran etexilate is used in combination with Pantoprazole resulting in a loss in efficacy.
ParecoxibParecoxib may increase the anticoagulant activities of Dabigatran etexilate.
ParnaparinParnaparin may increase the anticoagulant activities of Dabigatran etexilate.
ParoxetineThe serum concentration of Dabigatran etexilate can be increased when it is combined with Paroxetine.
Pentosan PolysulfateDabigatran etexilate may increase the anticoagulant activities of Pentosan Polysulfate.
PentoxifyllinePentoxifylline may increase the anticoagulant activities of Dabigatran etexilate.
PerindoprilThe serum concentration of Dabigatran etexilate can be increased when it is combined with Perindopril.
PethidineThe risk or severity of adverse effects can be increased when Dabigatran etexilate is combined with Pethidine.
PhenindioneDabigatran etexilate may increase the anticoagulant activities of Phenindione.
PhenobarbitalThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Phenobarbital.
PhenprocoumonDabigatran etexilate may increase the anticoagulant activities of Phenprocoumon.
PhenylbutazonePhenylbutazone may increase the anticoagulant activities of Dabigatran etexilate.
PimecrolimusPimecrolimus may increase the anticoagulant activities of Dabigatran etexilate.
PimozideThe serum concentration of Pimozide can be increased when it is combined with Dabigatran etexilate.
PirfenidonePirfenidone may increase the anticoagulant activities of Dabigatran etexilate.
PiroxicamPiroxicam may increase the anticoagulant activities of Dabigatran etexilate.
PlasminPlasmin may increase the anticoagulant activities of Dabigatran etexilate.
Platelet Activating FactorThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Platelet Activating Factor.
Polyestradiol phosphatePolyestradiol phosphate may decrease the anticoagulant activities of Dabigatran etexilate.
PonatinibThe serum concentration of Dabigatran etexilate can be increased when it is combined with Ponatinib.
PosaconazoleThe serum concentration of Dabigatran etexilate can be increased when it is combined with Posaconazole.
PrasugrelPrasugrel may increase the anticoagulant activities of Dabigatran etexilate.
PravastatinThe serum concentration of Dabigatran etexilate can be increased when it is combined with Pravastatin.
PrazosinThe serum concentration of Dabigatran etexilate can be increased when it is combined with Prazosin.
PrednisoneThe serum concentration of Dabigatran etexilate can be increased when it is combined with Prednisone.
ProbenecidThe serum concentration of Dabigatran etexilate can be increased when it is combined with Probenecid.
ProgesteroneThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Progesterone.
PromethazineThe serum concentration of Dabigatran etexilate can be increased when it is combined with Promethazine.
PropacetamolPropacetamol may increase the anticoagulant activities of Dabigatran etexilate.
PropafenoneThe serum concentration of Dabigatran etexilate can be increased when it is combined with Propafenone.
PropranololThe serum concentration of Dabigatran etexilate can be increased when it is combined with Propranolol.
Protein CDabigatran etexilate may increase the anticoagulant activities of Protein C.
ProtocatechualdehydeDabigatran etexilate may increase the anticoagulant activities of Protocatechualdehyde.
ProtriptylineThe serum concentration of Protriptyline can be increased when it is combined with Dabigatran etexilate.
PTC299PTC299 may increase the anticoagulant activities of Dabigatran etexilate.
QuercetinThe serum concentration of Dabigatran etexilate can be increased when it is combined with Quercetin.
QuinacrineThe serum concentration of Dabigatran etexilate can be increased when it is combined with Quinacrine.
QuinestrolQuinestrol may decrease the anticoagulant activities of Dabigatran etexilate.
QuinidineThe serum concentration of Dabigatran etexilate can be increased when it is combined with Quinidine.
QuinineThe serum concentration of Dabigatran etexilate can be increased when it is combined with Quinine.
RabeprazoleThe serum concentration of the active metabolites of Dabigatran etexilate can be reduced when Dabigatran etexilate is used in combination with Rabeprazole resulting in a loss in efficacy.
RanitidineThe serum concentration of Dabigatran etexilate can be increased when it is combined with Ranitidine.
RanolazineThe serum concentration of Dabigatran etexilate can be increased when it is combined with Ranolazine.
ReboxetineThe serum concentration of Dabigatran etexilate can be increased when it is combined with Reboxetine.
RegorafenibThe serum concentration of Dabigatran etexilate can be increased when it is combined with Regorafenib.
ReserpineThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Reserpine.
ResveratrolResveratrol may increase the anticoagulant activities of Dabigatran etexilate.
ReteplaseReteplase may increase the anticoagulant activities of Dabigatran etexilate.
ReviparinDabigatran etexilate may increase the anticoagulant activities of Reviparin.
RidogrelRidogrel may increase the anticoagulant activities of Dabigatran etexilate.
RifampicinThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Rifampicin.
RilpivirineThe serum concentration of Dabigatran etexilate can be increased when it is combined with Rilpivirine.
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Dabigatran etexilate.
RitonavirThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Ritonavir.
RivaroxabanDabigatran etexilate may increase the anticoagulant activities of Rivaroxaban.
RofecoxibRofecoxib may increase the anticoagulant activities of Dabigatran etexilate.
RolapitantThe serum concentration of Dabigatran etexilate can be increased when it is combined with Rolapitant.
RosiglitazoneRosiglitazone may increase the anticoagulant activities of Dabigatran etexilate.
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Dabigatran etexilate.
SalicylamideSalicylamide may increase the anticoagulant activities of Dabigatran etexilate.
Salicylic acidSalicylic acid may increase the anticoagulant activities of Dabigatran etexilate.
SalsalateSalsalate may increase the anticoagulant activities of Dabigatran etexilate.
SaquinavirThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Saquinavir.
SCH-530348SCH-530348 may increase the anticoagulant activities of Dabigatran etexilate.
ScopolamineThe serum concentration of Dabigatran etexilate can be increased when it is combined with Scopolamine.
SelegilineThe serum concentration of Dabigatran etexilate can be increased when it is combined with Selegiline.
SelexipagSelexipag may increase the anticoagulant activities of Dabigatran etexilate.
SeratrodastSeratrodast may increase the anticoagulant activities of Dabigatran etexilate.
SertralineThe serum concentration of Dabigatran etexilate can be increased when it is combined with Sertraline.
SevofluraneSevoflurane may increase the anticoagulant activities of Dabigatran etexilate.
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Dabigatran etexilate.
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Dabigatran etexilate.
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Dabigatran etexilate.
SirolimusThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Sirolimus.
SorafenibThe serum concentration of Dabigatran etexilate can be increased when it is combined with Sorafenib.
SpironolactoneThe serum concentration of Dabigatran etexilate can be increased when it is combined with Spironolactone.
SRT501SRT501 may increase the anticoagulant activities of Dabigatran etexilate.
St. John's WortThe serum concentration of Dabigatran etexilate can be decreased when it is combined with St. John&#39;s Wort.
StaurosporineThe serum concentration of Dabigatran etexilate can be increased when it is combined with Staurosporine.
StreptokinaseStreptokinase may increase the anticoagulant activities of Dabigatran etexilate.
StreptozocinThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Streptozocin.
SugammadexSugammadex may increase the anticoagulant activities of Dabigatran etexilate.
SulfasalazineSulfasalazine may increase the anticoagulant activities of Dabigatran etexilate.
SulfinpyrazoneSulfinpyrazone may increase the anticoagulant activities of Dabigatran etexilate.
SulindacSulindac may increase the anticoagulant activities of Dabigatran etexilate.
SulodexideDabigatran etexilate may increase the anticoagulant activities of Sulodexide.
SumatriptanThe serum concentration of Dabigatran etexilate can be increased when it is combined with Sumatriptan.
SunitinibThe serum concentration of Dabigatran etexilate can be increased when it is combined with Sunitinib.
SuprofenSuprofen may increase the anticoagulant activities of Dabigatran etexilate.
Synthetic Conjugated Estrogens, ASynthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Dabigatran etexilate.
Synthetic Conjugated Estrogens, BSynthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Dabigatran etexilate.
TacrineThe serum concentration of Dabigatran etexilate can be increased when it is combined with Tacrine.
TacrolimusThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Tacrolimus.
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Dabigatran etexilate.
TAK-390MRThe serum concentration of the active metabolites of Dabigatran etexilate can be reduced when Dabigatran etexilate is used in combination with TAK-390MR resulting in a loss in efficacy.
TamoxifenThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Tamoxifen.
Taurocholic AcidThe serum concentration of Dabigatran etexilate can be increased when it is combined with Taurocholic Acid.
TelmisartanThe serum concentration of Dabigatran etexilate can be increased when it is combined with Telmisartan.
TemsirolimusThe risk or severity of adverse effects can be increased when Dabigatran etexilate is combined with Temsirolimus.
TemsirolimusThe serum concentration of Dabigatran etexilate can be increased when it is combined with Temsirolimus.
TenecteplaseTenecteplase may increase the anticoagulant activities of Dabigatran etexilate.
TenoxicamTenoxicam may increase the anticoagulant activities of Dabigatran etexilate.
TepoxalinTepoxalin may increase the anticoagulant activities of Dabigatran etexilate.
TerazosinThe serum concentration of Dabigatran etexilate can be increased when it is combined with Terazosin.
TerfenadineThe serum concentration of Dabigatran etexilate can be increased when it is combined with Terfenadine.
TeriflunomideTeriflunomide may increase the anticoagulant activities of Dabigatran etexilate.
TesmilifeneThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Tesmilifene.
TestosteroneThe serum concentration of Dabigatran etexilate can be increased when it is combined with Testosterone.
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Dabigatran etexilate.
TianeptineThe serum concentration of Tianeptine can be increased when it is combined with Dabigatran etexilate.
Tiaprofenic acidTiaprofenic acid may increase the anticoagulant activities of Dabigatran etexilate.
TiboloneTibolone may increase the anticoagulant activities of Dabigatran etexilate.
TicagrelorTicagrelor may increase the anticoagulant activities of Dabigatran etexilate.
TiclopidineTiclopidine may increase the anticoagulant activities of Dabigatran etexilate.
TinzaparinTinzaparin may increase the anticoagulant activities of Dabigatran etexilate.
TipranavirThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Tipranavir.
TirofibanTirofiban may increase the anticoagulant activities of Dabigatran etexilate.
Tolfenamic AcidTolfenamic Acid may increase the anticoagulant activities of Dabigatran etexilate.
TolmetinTolmetin may increase the anticoagulant activities of Dabigatran etexilate.
TolvaptanThe serum concentration of Dabigatran etexilate can be increased when it is combined with Tolvaptan.
TositumomabThe risk or severity of adverse effects can be increased when Dabigatran etexilate is combined with Tositumomab.
TranilastTranilast may increase the anticoagulant activities of Dabigatran etexilate.
TrapidilTrapidil may increase the anticoagulant activities of Dabigatran etexilate.
TrazodoneThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Trazodone.
TreprostinilTreprostinil may increase the anticoagulant activities of Dabigatran etexilate.
TreprostinilThe risk or severity of adverse effects can be increased when Dabigatran etexilate is combined with Treprostinil.
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Dabigatran etexilate.
TrifluoperazineThe serum concentration of Dabigatran etexilate can be increased when it is combined with Trifluoperazine.
TriflupromazineThe serum concentration of Dabigatran etexilate can be increased when it is combined with Triflupromazine.
TriflusalTriflusal may increase the anticoagulant activities of Dabigatran etexilate.
TrimethoprimThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Trimethoprim.
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Dabigatran etexilate.
Trisalicylate-cholineTrisalicylate-choline may increase the anticoagulant activities of Dabigatran etexilate.
TroleandomycinThe serum concentration of Dabigatran etexilate can be increased when it is combined with Troleandomycin.
UrokinaseUrokinase may increase the anticoagulant activities of Dabigatran etexilate.
ValdecoxibValdecoxib may increase the anticoagulant activities of Dabigatran etexilate.
VenlafaxineThe serum concentration of Dabigatran etexilate can be increased when it is combined with Venlafaxine.
VerapamilThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Verapamil.
VinblastineThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Vinblastine.
VincristineThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Vincristine.
VinorelbineThe serum concentration of Dabigatran etexilate can be increased when it is combined with Vinorelbine.
Vitamin EVitamin E may increase the anticoagulant activities of Dabigatran etexilate.
VorapaxarThe risk or severity of adverse effects can be increased when Vorapaxar is combined with Dabigatran etexilate.
WarfarinDabigatran etexilate may increase the anticoagulant activities of Warfarin.
XimelagatranDabigatran etexilate may increase the anticoagulant activities of Ximelagatran.
ZaltoprofenZaltoprofen may increase the anticoagulant activities of Dabigatran etexilate.
ZeranolZeranol may decrease the anticoagulant activities of Dabigatran etexilate.
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Dabigatran etexilate.
ZileutonZileuton may increase the anticoagulant activities of Dabigatran etexilate.
ZimelidineThe serum concentration of Dabigatran etexilate can be increased when it is combined with Zimelidine.
ZomepiracZomepirac may increase the anticoagulant activities of Dabigatran etexilate.
Food Interactions
  • St. John's Wort

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Thrombospondin receptor activity
Specific Function:
Thrombin, which cleaves bonds after Arg and Lys, converts fibrinogen to fibrin and activates factors V, VII, VIII, XIII, and, in complex with thrombomodulin, protein C. Functions in blood homeostasis, inflammation and wound healing.
Gene Name:
F2
Uniprot ID:
P00734
Molecular Weight:
70036.295 Da
References
  1. Squizzato A, Dentali F, Steidl L, Ageno W: New direct thrombin inhibitors. Intern Emerg Med. 2009 Dec;4(6):479-84. doi: 10.1007/s11739-009-0314-8. Epub 2009 Sep 15. [PubMed:19756950 ]
  2. Liesenfeld KH, Schafer HG, Troconiz IF, Tillmann C, Eriksson BI, Stangier J: Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis. Br J Clin Pharmacol. 2006 Nov;62(5):527-37. [PubMed:17061960 ]
  3. Karthikeyan G, Eikelboom JW, Hirsh J: Dabigatran: ready for prime time? Pol Arch Med Wewn. 2010 Apr;120(4):137-42. [PubMed:20424539 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Triglyceride lipase activity
Specific Function:
Involved in the detoxification of xenobiotics and in the activation of ester and amide prodrugs. Hydrolyzes aromatic and aliphatic esters, but has no catalytic activity toward amides or a fatty acyl-CoA ester. Hydrolyzes the methyl ester group of cocaine to form benzoylecgonine. Catalyzes the transesterification of cocaine to form cocaethylene. Displays fatty acid ethyl ester synthase activity,...
Gene Name:
CES1
Uniprot ID:
P23141
Molecular Weight:
62520.62 Da
References
  1. Hu ZY, Parker RB, Herring VL, Laizure SC: Conventional liquid chromatography/triple quadrupole mass spectrometry based metabolite identification and semi-quantitative estimation approach in the investigation of in vitro dabigatran etexilate metabolism. Anal Bioanal Chem. 2013 Feb;405(5):1695-704. doi: 10.1007/s00216-012-6576-4. Epub 2012 Dec 14. [PubMed:23239178 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Methylumbelliferyl-acetate deacetylase activity
Specific Function:
Involved in the detoxification of xenobiotics and in the activation of ester and amide prodrugs. Shows high catalytic efficiency for hydrolysis of cocaine, 4-methylumbelliferyl acetate, heroin and 6-monoacetylmorphine.
Gene Name:
CES2
Uniprot ID:
O00748
Molecular Weight:
61806.41 Da
References
  1. Hu ZY, Parker RB, Herring VL, Laizure SC: Conventional liquid chromatography/triple quadrupole mass spectrometry based metabolite identification and semi-quantitative estimation approach in the investigation of in vitro dabigatran etexilate metabolism. Anal Bioanal Chem. 2013 Feb;405(5):1695-704. doi: 10.1007/s00216-012-6576-4. Epub 2012 Dec 14. [PubMed:23239178 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Retinoic acid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform has specificity for phenols. Isoform 2 lacks transferase activity but acts as a negative regulator of isoform 1.
Gene Name:
UGT1A9
Uniprot ID:
O60656
Molecular Weight:
59940.495 Da
References
  1. Ebner T, Wagner K, Wienen W: Dabigatran acylglucuronide, the major human metabolite of dabigatran: in vitro formation, stability, and pharmacological activity. Drug Metab Dispos. 2010 Sep;38(9):1567-75. doi: 10.1124/dmd.110.033696. Epub 2010 Jun 15. [PubMed:20551237 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Glucuronosyltransferase activity
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds.Its unique specificity for 3,4-catechol estrogens and estriol suggests it may play an important role in regulating the level and activity of these potent and active estrogen metabolites. Is also active with androsterone, hyodeoxycholic acid and tetrachlorocatechol...
Gene Name:
UGT2B7
Uniprot ID:
P16662
Molecular Weight:
60694.12 Da
References
  1. Ebner T, Wagner K, Wienen W: Dabigatran acylglucuronide, the major human metabolite of dabigatran: in vitro formation, stability, and pharmacological activity. Drug Metab Dispos. 2010 Sep;38(9):1567-75. doi: 10.1124/dmd.110.033696. Epub 2010 Jun 15. [PubMed:20551237 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Glucuronosyltransferase activity
Specific Function:
UDPGTs are of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isozyme displays activity toward several classes of xenobiotic substrates, including simple phenolic compounds, 7-hydroxylated coumarins, flavonoids, anthraquinones, and certain drugs and their hydroxylated metabolites. It also catalyzes the glucuronidatio...
Gene Name:
UGT2B15
Uniprot ID:
P54855
Molecular Weight:
61035.815 Da
References
  1. Ebner T, Wagner K, Wienen W: Dabigatran acylglucuronide, the major human metabolite of dabigatran: in vitro formation, stability, and pharmacological activity. Drug Metab Dispos. 2010 Sep;38(9):1567-75. doi: 10.1124/dmd.110.033696. Epub 2010 Jun 15. [PubMed:20551237 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Nadph dehydrogenase (quinone) activity
Specific Function:
The enzyme apparently serves as a quinone reductase in connection with conjugation reactions of hydroquinones involved in detoxification pathways as well as in biosynthetic processes such as the vitamin K-dependent gamma-carboxylation of glutamate residues in prothrombin synthesis.
Gene Name:
NQO2
Uniprot ID:
P16083
Molecular Weight:
25918.4 Da
References
  1. Michaelis S, Marais A, Schrey AK, Graebner OY, Schaudt C, Sefkow M, Kroll F, Dreger M, Glinski M, Koester H, Metternich R, Fischer JJ: Dabigatran and dabigatran ethyl ester: potent inhibitors of ribosyldihydronicotinamide dehydrogenase (NQO2). J Med Chem. 2012 Apr 26;55(8):3934-44. doi: 10.1021/jm3001339. Epub 2012 Apr 17. [PubMed:22494098 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Galanis T, Thomson L, Palladino M, Merli GJ: New oral anticoagulants. J Thromb Thrombolysis. 2011 Apr;31(3):310-20. doi: 10.1007/s11239-011-0559-8. [PubMed:21327511 ]
  2. Scaglione F: New oral anticoagulants: comparative pharmacology with vitamin K antagonists. Clin Pharmacokinet. 2013 Feb;52(2):69-82. doi: 10.1007/s40262-012-0030-9. [PubMed:23292752 ]
Comments
comments powered by Disqus
Drug created on May 03, 2010 12:25 / Updated on October 01, 2016 02:24